[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556219":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":28,"locations":39,"responsibleParty":85,"collaborators":87,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":99,"minAge":100,"maxAge":11,"enrollmentInfo":101,"targetDuration":11,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"High-resolution anoscopy","OTHER",null,[13],"Procedure: High-resolution anoscopy",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"PROCEDURE","The study includes 2 visits:\n\n* a medical consultation for inclusion\n* a proctology consultation including the performance of an AHR associated or not with biopsy sampling",[9],[20,24],{"name":21,"affiliation":22,"role":23},"Caroline Lascoux-Combe, Dr","Assistance Publique - Hôpitaux de Paris","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":26,"role":27},"David Veyer, Pharm D,PhD","Hôpital Européen Georges-Pompidou","STUDY_DIRECTOR",[29,35],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},"Fatoumata Coulibaly","CONTACT","0144236110","+33","fatoumata.coulibay@inserm.fr",{"name":36,"role":31,"phone":37,"phoneExt":33,"email":38},"Mathilde Ghislain, MSc","0145595229","mathilde.ghislain@inserm.fr",[40,59,73],{"facility":41,"status":42,"city":43,"state":11,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Hôpital de la Croix Rousse - SMIT","RECRUITING","Lyon","69004","France","FR",{"type":48,"coordinates":49},"Point",[50,51],4.84789,45.74906,{"lat":51,"lon":50},[54,57],{"name":55,"role":31,"phone":11,"phoneExt":11,"email":56},"Stanislas Ogoudjobi","stanislas.ogoudjobi@chu-lyon.fr",{"name":58,"role":23,"phone":11,"phoneExt":11,"email":11},"Dulce Alfaiate, Dr",{"facility":60,"status":42,"city":61,"state":11,"zip":62,"country":45,"countryCode":46,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Hôpital Saint-Louis - SMIT","Paris","75010",{"type":48,"coordinates":64},[65,66],2.3488,48.85341,{"lat":66,"lon":65},[69,72],{"name":70,"role":31,"phone":11,"phoneExt":11,"email":71},"Bénédicte Loze","benedicte.loze@aphp.fr",{"name":21,"role":23,"phone":11,"phoneExt":11,"email":11},{"facility":74,"status":42,"city":61,"state":11,"zip":75,"country":45,"countryCode":46,"cosmosGeoPoint":76,"geoPoint":78,"contacts":79},"Hôpital Tenon - SMIT","75020",{"type":48,"coordinates":77},[65,66],{"lat":66,"lon":65},[80,83],{"name":81,"role":31,"phone":11,"phoneExt":11,"email":82},"Thibaut Pélagie","pelagie.thibaut@aphp.fr",{"name":84,"role":23,"phone":11,"phoneExt":11,"email":11},"Gilles Pialoux, Pr",{"type":86,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[88],{"name":89,"class":90},"INSERM SC10-US19","UNKNOWN","100556219","identification-of-molecular-signatures-of-high-risk-oncogenic-hpv-and-study-of-their-associations-with-the-presence-of-high-grade-lesions-andor-anal-cancer-10-years-after-inclusion-in-the-anrs-ipergay-trial-100556219",false,"NCT06522256","Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and\u002For Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial","HPVsign","Inclusion Criteria:\n\n* Participant in the ANRS IPERGAY clinical trial who was included in the initial HPV sub-study;\n* Informed and written signed consent\n* Participant with regular health insurance\n\nExclusion Criteria:\n\n* Participant under guardianship or curatorship\n* Participant with free State medical assistance\n* Participant who disagrees with the use of data collected as part of their participation in the ANRS IPERGAY trial.",true,"ALL","18 Years",{"count":102,"type":103},100,"ESTIMATED","INTERVENTIONAL",[106],"NA","HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high-grade lesions and\u002For anal cancers using high-resolution anoscopy (HRA) during the HPVsign study and\u002For diagnosed since the end of participation in the ANRS IPERGAY trial.",[109,110],"HPV Infection","Anal Cancer",[112],"HSIL","2025-11-27",{"date":115,"type":116},"2025-12-04","ACTUAL",{"date":118,"type":116},"2025-03-20",{"date":120,"type":103},"2027-07-30",{"name":5,"class":6},3]